These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20600017)

  • 1. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
    Nelson DR; Benhamou Y; Chuang WL; Lawitz EJ; Rodriguez-Torres M; Flisiak R; Rasenack JW; Kryczka W; Lee CM; Bain VG; Pianko S; Patel K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
    Gastroenterology; 2010 Oct; 139(4):1267-76. PubMed ID: 20600017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
    Zeuzem S; Sulkowski MS; Lawitz EJ; Rustgi VK; Rodriguez-Torres M; Bacon BR; Grigorescu M; Tice AD; Lurie Y; Cianciara J; Muir AJ; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
    Gastroenterology; 2010 Oct; 139(4):1257-66. PubMed ID: 20600013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
    Pianko S; Zeuzem S; Chuang WL; Foster GR; Sarin SK; Flisiak R; Lee CM; Andreone P; Piratvisuth T; Shah S; Sood A; George J; Gould M; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Li Y; Pang M; Yin Y; Feutren G; Jacobson IM;
    J Viral Hepat; 2012 Sep; 19(9):623-34. PubMed ID: 22863266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
    Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
    Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
    Nelson DR; Rustgi V; Balan V; Sulkowski MS; Davis GL; Muir AJ; Lambiase LR; Dickson RC; Weisner RH; Fiscella M; Cronin PW; Pulkstenis E; McHutchison JG; Subramanian GM
    Clin Gastroenterol Hepatol; 2009 Feb; 7(2):212-8. PubMed ID: 19061971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
    Jin YJ; Lee JW; Lee JI; Park SH; Park CK; Kim YS; Jeong SH; Kim YS; Kim JH; Hwang SG; Rim KS; Yim HJ; Cheong JY; Cho SW; Lee JS; Park YM; Jang JW; Lee CK; Sohn JH; Yang JM; Han S
    BMC Gastroenterol; 2013 Apr; 13():74. PubMed ID: 23627926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.
    Neumann AU; Bain VG; Yoshida EM; Patel K; Pulkstenis E; Subramanian GM
    Liver Int; 2009 Oct; 29(9):1350-5. PubMed ID: 19291180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.
    Neumann AU; Pianko S; Zeuzem S; Yoshida EM; Benhamou Y; Mishan M; McHutchison JG; Pulkstenis E; Mani Subramanian G
    J Hepatol; 2009 Jul; 51(1):21-8. PubMed ID: 19447518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
    Foster GR; Zeuzem S; Pianko S; Sarin SK; Piratvisuth T; Shah S; Andreone P; Sood A; Chuang WL; Lee CM; George J; Gould M; Flisiak R; Jacobson IM; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Sola R; Messina I; Yin Y; Cammarata S; Feutren G; Brown KK
    J Viral Hepat; 2013 Apr; 20(4):e115-23. PubMed ID: 23490379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
    Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
    Bain VG; Kaita KD; Marotta P; Yoshida EM; Swain MG; Bailey RJ; Patel K; Cronin PW; Pulkstenis E; McHutchison JG; Subramanian GM
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):701-6. PubMed ID: 18467185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
    Roberts SK; Weltman MD; Crawford DH; McCaughan GW; Sievert W; Cheng WS; Rawlinson W; Desmond PV; Marks PS; Yoshihara M; Rizkalla B; Depamphilis JK; Dore GJ;
    Hepatology; 2009 Oct; 50(4):1045-55. PubMed ID: 19676125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
    Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.
    Al Ashgar H; Helmy A; Khan MQ; Al Kahtani K; Al Quaiz M; Rezeig M; Kagevi I; Alshehri A; Al Kalbani A; Al Swat K; Dahab S; Elkum N; Al Fadda M
    Ann Saudi Med; 2009; 29(1):4-14. PubMed ID: 19139619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.